Harborside Press, LLC, announces the newly redesigned Web site of the Journal of the Advanced Practitioner in Oncology (JADPRO). The new Web site features an oncology news feed, opportunities for Continuing Education credits, as well as content from current and past issues. In addition, JADPRO has also launched its newest installment in social media, the Facebook page for the Journal of the Advanced Practitioner in Oncology.

The JADPRO Web site homepage highlights a news feed of oncology reports from the Web. This feed includes links to relevant, breaking news reports that are important to advanced practitioners working in cancer. The feed will help keep advanced practitioners up-to-date with developing stories in oncology, not only for their own professional development, but also for the questions they often face from their patients.

The Web site will also feature key editorials and commentary, selected articles from previous issues, virtual events, JADPRO’s most recent social media posts, blog entries from JADPRO associate editors and guests, and sponsored content. From the navigation bar, potential contributors can access the manuscript submission portal ScholarOne and clinicians can sign up to receive the journal.

“We have received many requests to build a collaborative community, allowing our readers to voice their opinions, share knowledge, and work together. The new JADPRO Web site and Facebook page will provide us with the opportunity to engage our readers, offer a variety of insightful commentary, and strengthen our commitment to this profession, as well as provide our readers with a new venue to learn about our products and events,” said Conor Lynch, Executive Vice President, Editorial, of Harborside Press.

Facebook is one of the most popular Internet Web sites by traffic, with over 800 million registered users.

Harborside Press publishes the Journal of the Advanced Practitioner in Oncology, whose mission is to improve the quality of care for patients with cancer, support critical issues in advanced practice in oncology, and recognize the expanding contributions of advanced practitioners in oncology. The essential objectives of JADPRO are:

• To publish topics across the cancer trajectory for the nurse practitioner, clinical nurse specialist, and physician assistant
• To support professional development of the advanced practitioner in oncology
• To promote interprofessional collaboration
• To uphold the highest ethical and professional standards
• To provide information that will enhance the quality of care for the patient with cancer

For more information, please contact Melanie Serge at Melanie@harborsidepress.com or visit us at: http://www.advancedpractitioner.com

###

Harborside Interactive is a developer of digital solutions for the pharmaceutical, biotech, and manufacturing industries, as well as medical media companies. Harborside Press’ wealth of experience in the medical communications field, along with its excellent relationships with some of the most important clinicians and organizations in oncology, makes Harborside Interactive uniquely positioned to understand the relationship between clients and their intended audience.

The employees of Harborside Interactive have experience in Web development, mobile application production, content management systems, relational database administration, clinician- and patient-targeted communications, closed-loop marketing, online CE/CME, virtual meeting and convention solutions, mobile- and PC-based gaming, social network based strategies, and analytics, as well as working with internal and external regulatory requirements.

“This new division will allow us to better serve our existing clients’ digital needs while also allowing us to pursue creative paths toward new multimedia offerings in our industry,” said Anthony Cutrone, President of Harborside Press. “Successful publishing demands that we provide our content in multiple formats with multiple points of access, and Harborside Interactive will help us meet these needs.”

Harborside Press is the publisher of JNCCN–The Journal of the National Comprehensive Cancer Network, The ASCO Post, and the Journal of the Advanced Practitioner in Oncology.

Leading Harborside Interactive will be Frank Buchner, formerly the Chief Technical Officer of Euro RSCG Life in New York, NY. In this position, Mr. Buchner oversaw the information architecture, project management, flash development, database, quality assurance, and programming staff of his former company. He also developed applications (desktop and web) for company staff. Before joining Euro RSCG Life, Mr. Buchner was the Research and Development Manager for PRR, Inc., one of the leading publishers of oncology-specific journals and newspapers in the world.

“We are thrilled to have Frank joining our team,” said Jack Gentile, Chairman of Harborside Press. “We’ve had the good fortune to work with Frank in previous years, and his extensive knowledge both of the medical communications industry along with its technical demands will ensure the success of this new venture.”

“It’s a very exciting opportunity.” said Mr. Buchner. “The latest social and mobile technologies render huge opportunities for our clients to enhance the value proposition for their brands and customers. Integrated campaigns leveraging cutting edge technology combined with HSP’s publications will open up a whole new avenue of unique and innovative offerings.”

Harborside Interactive will be located in Cold Spring Harbor, NY, at the location of Harborside Press.

About Harborside Press

Harborside Press is a medical publishing company based in Cold Spring Harbor, New York. Its leadership and management team has more than 50 years of experience in the field, including extensive success in building and leading editorial teams for a number of publications. Harborside Press is the current publisher of JNCCN–The Journal of the National Comprehensive Cancer Network and the Journal of the Advanced Practitioner in Oncology, and also publishes The ASCO Post under a collaborative arrangement with the American Society of Clinical Oncology. For more information on Harborside Press or Harborside Interactive, please visit http://www.HarborsidePress.com.

###

“It is important that the breast cancer community rest assured that ODAC is an independent, unbiased panel of experts in oncology whose mission is to provide their best objective scientific and clinical recommendations to the FDA for drug approval,” said ODAC Chair, Wyndham Wilson, MD, PhD. Dr. Wilson is Chief of the Lymphoid Therapeutics Section of the Center for Cancer Research, National Cancer Institute.

Bevacizumab is currently approved in combination with paclitaxel for the first-line treatment of advanced HER2-negative breast cancer, based on encouraging results of the E2100 trial (N Engl J Med 357:2666-2676, 2007). The FDA provisionally granted accelerated approval but requested confirmatory data from the manufacturer, Genentech. In November 2009, Genentech supplied the results of the AVADO (J Clin Oncol 28:3239-3247, 2010) and RIBBON-1 trials (J Clin Oncol 27(abstract 1005), 2009). On July 20, 2010, ODAC recommended against conversion to full approval.

Joanne Mortimer, MD, a member of ODAC, who voted to approve bevacizumab in advanced breast cancer in December 2007 based on the E2100 study, said, “The additional data from AVADO and RIBBON-1 supported an increased response rate, but also confirmed the increased toxicity and lack of survival advantage with bevacizumab. Like the majority of panel [ODAC] members, I could not recommend approval.” Dr. Mortimer is Director of the Women’s Cancers’ Program and Professor of Medical Oncology and Experimental Therapeutics at City of Hope Comprehensive Cancer Center in Duarte, CA.

Gabriel Hortobagyi, MD, who attended the ODAC meeting as a consultant to Genentech, said “There is an urgent need for the FDA and the cancer community to agree upon exactly what qualifies a drug for approval.” Dr. Hortobagyi is Professor of Medicine and Chairman, Department of Breast Medical Oncology, at The University of Texas M.D. Anderson Cancer Center in Houston, TX. “There would certainly be differences of opinion from the various corners as to the requisite degree of benefit,” he added, but “by having this conversation we should arrive at what is commensurate with the expectations for advanced breast cancer.”

“If we only accepted cancer treatments that improve survival, we would severely limit options for our patients,” said Edith P. Perez, MD, Director of the Breast Cancer Program and Professor of Medicine at Mayo Clinic in Jacksonville, FL.

A decision by FDA on bevacizumab’s breast cancer indication is expected later this year.

About The ASCO Post

The ASCO Post is a newspaper intended for everyone with an interest in oncology. The ASCO Post serves a broad audience of oncology professionals and covers a wide scope of topics, including clinical cancer research, policy developments, and oncology practice issues. As a benefit of membership, the print edition is distributed to all U.S. ASCO members.  U.S. and international ASCO members also receive complimentary online access.  In addition, non-ASCO member medical oncologists, hematologists, and hematologist/oncologists in the United States will be eligible for a complimentary subscription.

About Harborside Press

Harborside Press is a medical publishing company based in Cold Spring Harbor, New York. Its leadership and management team has more than 50 years of experience in the field, including extensive success in building and leading editorial teams for a number of publications.  Harborside Press is the current publisher of JNCCN–The Journal of the National Comprehensive Cancer Network and The Journal of the Advanced Practitioner in Oncology. Harborside Press publishes The ASCO Post under a license arrangement with the American Society of Clinical Oncology.  For more information on Harborside Press, please visit www.HarborsidePress.com.

Although the formal agreement is still in development, ASCO and Harborside Press plan to publish the first issue in June 2010, with a launch at ASCO’s 46th Annual Meeting. The publication will also be available online at www.ASCOPost.com, which will be updated frequently with the latest news and information.

“After studying the environment, we recognized the need for highly validated reporting on need-to-know cancer research and policy news, patient care and clinical practice issues, as well as thoughtful commentary from leaders in the field,” said Dr. Allen Lichter, CEO of ASCO. “As the professional society that promotes and advances the highest quality multidisciplinary cancer care, we have a unique responsibility to help our community stay current in the fast-changing world of clinical oncology. We look forward to working with Harborside Press to provide this new addition to ASCO’s list of award winning publications for oncology professionals.”

“We are thrilled to collaborate with ASCO on the launch of The ASCO Post,” said Jack Gentile, Chairman of Harborside Press. “Our experience in oncology publishing, combined with ASCO’s expertise and leadership in the cancer community, make us an exceptional team.”

The ASCO Post will serve a broad audience of oncology professionals and cover a wide scope of topics, including clinical cancer research released at medical meetings and in journals worldwide, policy developments and oncology practice issues. The publication will include news stories and briefs, feature articles, and commentary on the latest developments in oncology. A portion of the publication will be dedicated to reporting on ASCO news and events.

The ASCO Post will initially be published monthly, with the goal of increasing publication to 18 to 24 times per year after the first year. It will be overseen by a pre-eminent oncologist editor-in-chief (to be named in the coming months) and an editorial board of recognized leaders in oncology. Harborside Press will be responsible for the day-to-day management of the publication and its reporting staff, which will include a team of science writers with extensive experience in oncology reporting.

Audience and Subscriptions
The ASCO Post is intended for everyone with an interest in oncology. As a benefit of membership, the print edition will be distributed to all U.S. ASCO members. U.S. and international ASCO members will receive complimentary online access. In addition, non-ASCO member medical oncologists, hematologists and hematologist/oncologists in the United States will be eligible for a complimentary subscription.

The annual subscription cost for all other subscribers will be $75 for the print or the online edition, and $125 for both editions. For other interested subscribers living outside of the United States, the price will be $125 and $175, respectively.

About the American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 28,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. For ASCO information and resources, visit www.asco.org/presscenter. Patient-oriented cancer information is available at www.Cancer.Net.

About Harborside Press
Harborside Press (formerly known as Cold Spring Publishing) is a medical publishing company based in Cold Spring Harbor, New York. Its leadership and management team has more than 50 years of experience in the field, including extensive success in building and leading editorial teams for a number of publications. Harborside Press is the current publisher of JNCCN–The Journal of the National Comprehensive Cancer Network and The Journal of the Advanced Practitioner in Oncology. For more information on Harborside Press, please visit www.HarborsidePress.com.

###

In addition, Harborside Press was pleased to announce that the growth the company has experienced over the past year requires a substantial expansion in personnel and a move to larger office space. As of January 1, 2010, the new offices of Harborside Press will be located at 37 Main Street, Cold Spring Harbor, NY 11724. The phone numbers will remain the same: 631-692-0800 (p) and 631-692-0805 (f). The company’s Web site is www.HarborsidePress.com.

Harborside Press, LLC, (HSP) is a medical publishing company whose principals have more than 50 years of combined publishing experience, with a specific focus in oncology. HSP publishes JNCCN — The Journal of the National Comprehensive Cancer Network, which covers the entire spectrum of cancer care and features updates on the NCCN Clinical Practice Guidelines in Oncology(TM). HSP also publishes the NCCN Highlights series and the forthcoming Journal of the Advanced Practitioner in Oncology, as well as custom publications of textbooks, monographs, and patient educational materials. The company’s principals include the former Publisher of the journal ONCOLOGY and Oncology News International and the former Publisher and Executive Editor of The Journal of Supportive Oncology, Community Oncology, and The Oncology Report. The principals of Harborside Press are John A. Gentile, Jr., Anthony J. Cutrone, and Conor Lynch.

With a target circulation of over 7,000, the journal will be distributed at no charge to qualifying recipients in the United States. The inaugural issue is scheduled for launch in May 2010, and the journal will then publish 6 times a year.

“Even with the many advances seen in prevention, treatment, and care, the number of people diagnosed and living with cancer is on the rise,” said Anthony Cutrone, President of Harborside Press. “Advanced practitioners play a pivotal role in patient care, yet they do not have a publication written by their colleagues that address their specific editorial needs. We believe that will fill this publication gap.”

The journal content will include clinical reviews, original research, translational research summaries, pharmacologic reviews, case studies, national practice profiles, news updates, professional development articles, patient information, and more. The journal will also have an on-line platform at www.advancedpractitioner.com.

Pamela Hallquist Viale, RN, MS, CS, ANP, AOCNP, will serve as the Editor-in-Chief of Ms. Viale has over 25 years of experience as an oncology nurse, clinical nurse specialist and oncology nurse practitioner, and is currently an oncology nurse consultant and Assistant Clinical Professor at the University of California, San Francisco, School of Nursing. She has published and lectured widely on a number of topics, with a focus on symptom management and colorectal cancer.

“Advanced practitioners are challenging to reach,” said Ms. Viale, “as they seek updates from both journals targeted to nurses and journals targeted to physicians. My hope is that will provide our readers with useful clinical and professional information that will make them better equipped to care for their patients.”

“Harborside Press is very fortunate to announce Pamela Viale as the Editor-in-Chief of ,”said John A. Gentile, Jr., Publisher of the journal. “Her experience — as a clinician, researcher, educator, and writer — makes her the ideal candidate to lead this publication.”

For information regarding advertising opportunities in please contact David Horowitz, Director of Business Development, at 631-692-0800, x304.

Harborside Press, LLC, (HSP) is a medical publishing company whose principals have more than 50 years of combined publishing experience, with a specific focus in oncology. HSP publishes which covers the entire spectrum of cancer care and features updates on the NCCN Clinical Practice Guidelines in Oncology(TM). HSP also publishes the series and the forthcomingas well as custom publications of textbooks, monographs, and patient educational materials. Visit Harborside Press on the Web at www.harborsidepress.com.

SOURCE Cold Spring Publishing, LLC

CONTACT: Conor Lynch, Executive Editor, Cold Spring Publishing, LLC,+1-631-692-0800

Jack Gentile, Chairman and Principal of Cold Spring Publishing, was the founder and president of PRR, Inc., a leading oncology publishing company in the United States. PRR, Inc. published the highly respected journal Oncology, the second most widely read journal in the field of oncology, as well as Oncology News International, Cancer Management Handbook, Primary Care & Cancer, and several educational programs directed specifically to the oncology specialty.

Conor Lynch, Executive Editor and Principal of Cold Spring Publishing, is former Executive Editor for Elsevier Oncology, publisher of The Journal of Supportive Oncology, Community Oncology, and The Oncology Report.

“Cold Spring Publishing’s leadership has more than 40 years of experience in the field of academic oncology that includes extensive success in building and leading editorial teams and developing innovative service offerings,” says William T. McGivney, PhD, Chief Executive Officer, NCCN. “We are pleased to appoint Mr. Gentile and his team; their skills and experience are a perfect fit with NCCN’s strategy to continue to drive the growth and development of our journal, JNCCN.”

JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology™, review articles elaborating on NCCN Guideline recommendations, and health services and clinical research papers. Content covers the entire spectrum of oncologic health care from prevention and screening to treatment and supportive care.

JNCCN is ranked seventh in both readership and reader advertising exposure among the top oncology publications, according to FOCUS, a leading readership-measurement company for medical journals.

The March issue of JNCCN will be the first issue published by Cold Spring Publishing.

For questions about NCCN or for interview information, please contact Megan Martin 215.690.0576.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.

The NCCN Member Institutions are:

• City of Hope Comprehensive Cancer Center
• Dana-Farber/Brigham and Women’s Cancer Center
  Massachusetts General Hospital Cancer Center
• Duke Comprehensive Cancer Center
• Fox Chase Cancer Center
• Huntsman Cancer Institute at the University of Utah
• Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Robert H. Lurie Comprehensive Cancer Center of Northwestern University
• Memorial Sloan-Kettering Cancer Center
• H. Lee Moffitt Cancer Center & Research Institute
• The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
• Roswell Park Cancer Institute
• Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
• St. Jude Children’s Research Hospital / University of Tennessee Cancer Institute
• Stanford Comprehensive Cancer Center
• University of Alabama at Birmingham Comprehensive Cancer Center
• UCSF Helen Diller Family Comprehensive Cancer Center
• University of Michigan Comprehensive Cancer Center
• UNMC Eppley Cancer Center at The Nebraska Medical Center
• The University of Texas MD Anderson Cancer Center
• Vanderbilt-Ingram Cancer Center